AbbVie Inc has raised the bar for oncology acquisitions with an agreement to buy Pharmacyclics Inc and its recently approved drug Imbruvica (ibrutinib) for blood cancers for a cash and share offer totaling $21 billion. The deal has been approved by the boards of both companies.
